eli lilly retatrutide clinical trials Retatrutide, the next generation of GLP-1 drug from Lilly, helped participants lose an average of 71.2 pounds and reduce knee arthritis pain in a late-stage trial, the company announced. In Retatrutide Weight-Loss Drug Meets Phase

Compared to the control group, there were no significant differences in the clinical pregnancy rate or live birth rate among women receiving CoQ10 treatment for each embryo transfer or complete stimulation cycle ( CoQ10 in combination therapy The application of CoQ10 in reproductive medicine is significantly enhanced when used in conjunction with adjunct therapies

Then again, anything over 0 was an improvement, ha

Tirzepatide, the newest medication for type 2 diabetes: a review of the literature and implications for clinical practice

The hospital pharmacies segment dominated the market with a 46.80% share in 2025, owing to the high volume of diabetes and obesity prescriptions initiated within hospital and specialty care settings